Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jeanne Lenzer
  1. New York

    Pfizer, the world's largest drug maker, pleaded guilty on 13 May to numerous civil and criminal charges for illegally promoting the off-label use of gabapentin (Neurontin). It has agreed to pay a $240m (£136m; €200m) criminal fine and $152m to state and federal healthcare programmes. The fine is the second largest given in the industry.

    Meanwhile, off-label sales of gabapentin continue to soar, despite evidence that the drug is not effective for some of the problems it is used to treat.

    David Franklin, 42, a microbiologist and former Harvard …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular